ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,703 | +12.5% | 75,462 | +101.9% | 0.00% | 0.0% |
| Q2 2023 | $356,136 | -17.8% | 37,370 | -5.1% | 0.00% | 0.0% |
| Q1 2023 | $433,081 | -26.2% | 39,371 | -0.7% | 0.00% | -50.0% |
| Q4 2022 | $586,894 | -27.0% | 39,655 | -5.8% | 0.00% | -33.3% |
| Q3 2022 | $804,000 | +33.8% | 42,081 | +49.3% | 0.00% | +50.0% |
| Q2 2022 | $601,000 | +23.4% | 28,192 | +11.4% | 0.00% | +100.0% |
| Q1 2022 | $487,000 | -7.2% | 25,300 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $525,000 | -13.1% | 25,300 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $604,000 | -12.5% | 25,300 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $690,000 | -5.7% | 25,300 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $732,000 | +2.8% | 25,300 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $712,000 | +51.8% | 25,300 | +58.1% | 0.00% | +100.0% |
| Q3 2020 | $469,000 | -3.1% | 16,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $484,000 | +1.5% | 16,000 | 0.0% | 0.00% | -50.0% |
| Q1 2020 | $477,000 | – | 16,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |